{
  "id": 1770485,
  "title": "Marsh & McLennan Stock: Is Wall Street Bullish or Bearish?",
  "url": "https://urgent.news/2026/08/17/marsh-mclennan-stock-is-wall-street-bullish-or-bearish",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T09:49:05.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/marsh-mclennan-stock-wall-street-094905795.html"
  },
  "original_language": "en",
  "account": "Marsh & McLennan Companies, Inc. (MRSH), a global professional services and risk advisory firm with a market capitalization of $89.6 billion, has seen its stock underperform the broader market in recent times. Over the past 52 weeks, MRSH shares have declined by 9.3%, while the S&P 500 Index has gained 20.4%. On a year-to-date basis, MRSH shares are up 1.2%, compared to the S&P 500's 13.7% gain. The company's shares have also underperformed the State Street Financial Select Sector SPDR ETF, which has risen by 9.7% over the past 52 weeks and 6.2% in 2026.\n\nIn its Q2 FY2026 earnings report released on July 21, Marsh & McLennan's shares dropped 3.1% following weak performance at Guy Carpenter, ongoing reinsurance pricing pressure, and modest beat against high expectations. Despite this, the company reported a 6.2% year-over-year increase in consolidated revenue to approximately $7.40 billion, with underlying revenue growth of 5%. Adjusted operating income grew by 5.3% year-over-year to $2.17 billion, reflecting ongoing operating leverage, and adjusted EPS increased by 8.8% to $2.96, surpassing consensus estimates of around $2.90.\n\nAnalysts anticipate continued EPS growth for Marsh & McLennan, with a projected 7% year-over-year increase to $10.43 for the fiscal year ending in December 2026. Currently, the consensus rating among the 25 analysts covering the stock is a Moderate Buy, based on seven Strong Buy ratings, 17 Holds, and one Moderate Sell. This represents a bearish sentiment compared to a month ago when the stock had eight Strong Buy suggestions. On July 27, UBS analyst Brian Meredith upgraded MRSH to a Buy rating and raised his price target to $216 from $212, representing a 7.8% premium over MRSH's current price. The Street-high price target of $234 suggests a potential upside of 24.6%.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}